Company profile: SamanTree Medical
1.1 - Company Overview
Company description
- Provider of confocal microscopy-based intraoperative imaging solutions for cancer surgery, enabling accurate full margin control and immediate visualization of excised human tissue specimens. Offers the Histolog Scanner, Histolog Dip stain, Histolog Dish protection, Histolog Viewer software, and Histolog Digital Solution for image management, storage, sharing, and remote collaboration.
Products and services
- Histolog Scanner: Confocal microscopy–based device imaging the surface of excised human tissue, delivering high-resolution images for immediate cancer cell visualization and accurate, full margin control in the operating room
- Histolog Viewer: Software-based image management system architected to examine, manage, and share digital images and metadata from the Histolog Scanner
- Histolog Digital Solution: Remote-work–oriented platform enabling easy storing and sharing of Histolog Scanner images, facilitating collaboration with doctors or pathologists
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SamanTree Medical
Ayala Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule therapeutics, including gamma secretase inhibitors that block Notch-pathway activation. Pipeline includes AL101 in Phase 2 for recurrent/metastatic adenoid cystic carcinoma and AL102 in Phase 2/3 for desmoid tumors, with a planned Phase 2 in relapsed/refractory T-cell acute lymphoblastic leukemia. Conducts clinical trials to evaluate safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ayala Pharmaceuticals company profile →
Cellcentric
HQ: United Kingdom
Website
- Description: Provider of clinical-stage biotechnology therapies targeting p300/CBP inhibition to treat specific cancers, particularly solid tumors; developing the oral drug Inobrodib, currently in Phase I/II trials, with potential utility in non-small cell lung, breast, colon cancers and multiple myeloma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellcentric company profile →
Wugen
HQ: United States
Website
- Description: Provider of off-the-shelf allogeneic cellular therapies for solid tumors and hematologic malignancies, including WU-NK-101, a memory NK cell therapy, and WU-CART-007, a CD7-targeting CAR-T for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; plus Memory NK and CAR-T platforms enabling feeder-free cryopreserved NK cells and donor-derived CAR-T cells engineered to reduce fratricide and Graft vs. Host Disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wugen company profile →
Arvinas
HQ: United States
Website
- Description: Provider of PROTAC protein degrader therapies that harness the body's natural protein disposal system to degrade disease-causing proteins for life-threatening diseases, from discovery to commercialization. Pipeline includes vepdegestrant (ER+ breast cancer), ARV-766 (licensed to Novartis; prostate cancer), ARV-393 (BCL6), ARV-102 (LRRK2), and alpha-synuclein degraders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arvinas company profile →
ArcherDX
HQ: United States
Website
- Description: Provider of NGS-based assay solutions advancing molecular pathology, using proprietary Anchored Multiplex PCR (AMP) chemistry and Archer Analysis software to detect genetic mutations for solid tumor, blood cancer, and genetic disease research. Offers VARIANTPlex DNA panels, FUSIONPlex RNA panels, LIQUIDPlex ctDNA panels, IMMUNOVerse immune profiling assays, and an Assay Marketplace for custom NGS panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArcherDX company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SamanTree Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SamanTree Medical
2.2 - Growth funds investing in similar companies to SamanTree Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SamanTree Medical
4.2 - Public trading comparable groups for SamanTree Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →